185 related articles for article (PubMed ID: 22517003)
1. [Detection and clinical value of epithelial cellular adhesion molecule (EpCAM) mRNA positive circulating tumor cells in metastatic breast cancer].
Yan Y; Cheng JP; Di LJ; Song GH; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):275-80. PubMed ID: 22517003
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
3. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
[TBL] [Abstract][Full Text] [Related]
4. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
[TBL] [Abstract][Full Text] [Related]
7. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
8. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
[TBL] [Abstract][Full Text] [Related]
10. A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads.
Kim YJ; Koo GB; Lee JY; Moon HS; Kim DG; Lee DG; Lee JY; Oh JH; Park JM; Kim MS; Woo HG; Kim SI; Kang P; Choi W; Sim TS; Park WY; Lee JG; Kim YS
Biomaterials; 2014 Aug; 35(26):7501-10. PubMed ID: 24917030
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
[TBL] [Abstract][Full Text] [Related]
12. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
[TBL] [Abstract][Full Text] [Related]
13. Demasking of epithelial cell adhesion molecule (EpCAM) on circulating epithelial tumor cells by Tween®20 treatment in breast cancer patients.
Hekimian K; Stein EL; Pachmann U; Pachmann K
Clin Chem Lab Med; 2012 Dec; 50(4):701-8. PubMed ID: 22505561
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
[TBL] [Abstract][Full Text] [Related]
16. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.
Driemel C; Kremling H; Schumacher S; Will D; Wolters J; Lindenlauf N; Mack B; Baldus SA; Hoya V; Pietsch JM; Panagiotidou P; Raba K; Vay C; Vallböhmer D; Harréus U; Knoefel WT; Stoecklein NH; Gires O
Oncogene; 2014 Oct; 33(41):4904-15. PubMed ID: 24141784
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells and EpCAM expression in neuroendocrine tumors.
Khan MS; Tsigani T; Rashid M; Rabouhans JS; Yu D; Luong TV; Caplin M; Meyer T
Clin Cancer Res; 2011 Jan; 17(2):337-45. PubMed ID: 21224371
[TBL] [Abstract][Full Text] [Related]
19. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
Rini BI; Weinberg V; Shaw V; Scott J; Bok R; Park JW; Small EJ
Cancer; 2004 Jul; 101(1):90-5. PubMed ID: 15221993
[TBL] [Abstract][Full Text] [Related]
20. Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer.
Yang X; Wang X; Shen H; Deng R; Xue K
Cell Biochem Biophys; 2015 Sep; 73(1):87-91. PubMed ID: 25669446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
